Effective wound treatment largely depends on the use of materials capable of maintaining a moist environment, protecting the damaged tissue from infection, and promoting tissue regeneration. In this context, considerable attention has been focused on natural polysaccharides due to their excellent biocompatibility, biodegradability, and broad potential for functional modification. Among these, konjac glucomannan has attracted particular interest as a natural biopolymer with pronounced hydrophilic and gel-forming properties. Aim. To systematize current scientific data on the application of konjac glucomannan in wound dressing technology, analyze its properties as a biomaterial, and summarize research findings on the development of hydrogels, films, sponges, and fibers based on this polysaccharide. Materials and Methods. An analytical review of scientific publications indexed in the international databases PubMed, Scopus, Web of Science, and Google Scholar was conducted. Konjac glucomannan was found to possess high water-retention capacity, biocompatibility, low toxicity, and the ability to form three-dimensional polymer networks. Analysis of the literature confirmed its effective use in composite materials with xanthan gum, chitosan, Bletilla striata polysaccharides, gelatin, and other polymeric components. These composites exhibit improved mechanical and adhesive properties, maintain a moist wound environment, provide controlled release of bioactive compounds, and promote favorable conditions for tissue repair. Experimental studies demonstrated that konjac glucomannan-based materials stimulate cell migration, angiogenesis, collagen synthesis, and epithelialization. Furthermore, modification with bioactive compounds or antimicrobial agents imparts anti-inflammatory and antimicrobial properties, enhancing wound healing. Konjac glucomannan is a promising natural biopolymer for the development of modern wound dressings. Its physicochemical properties and compatibility with other biopolymers enable the fabrication of materials with enhanced functional characteristics, supporting further research aimed at developing innovative wound care products.
Enterosorbents based on highly dispersed silicon dioxide are among the most widely used agents of sorption therapy. This paper briefly highlights the history of their introduction into medical practice in Ukraine and outlines current trends in the development of this area, in particular the transition from powders to gel-like forms and the use of silicon dioxide obtained by precipitation along with fumed silica. The aim of this work was to demonstrate the enhanced protein sorption activity of innovative gel-like silica-containing enterosorbents compared to individual silicas in powder form (the “superactivity” effect) and to substantiate the possible mechanisms of this phenomenon based on the results of some physicochemical studies. The objects of the study were fumed and precipitated silicon dioxides, as well as gel-like enterosorbents developed on their basis. Protein sorption activity was evaluated using gelatin adsorption as a model protein. Infrared (IR) spectroscopy was employed to investigate intermolecular interactions between the components of the sorption system, whereas thermogravimetric analysis was used to assess the state of bound water and the structural organization of the gels. It was shown that the gel-like enterosorbents based on fumed and precipitated silica exhibited a significantly higher capacity for gelatin adsorption compared with the parent silicas. This effect was found to be associated with the presence of highly hydrophilic polysaccharides, namely sodium carboxymethylcellulose and sodium alginate, in the gel composition. IR spectroscopic data indicate the formation of an extensive hydrogen-bonding network between the functional groups of the protein and the silica-polysaccharide matrix, as evidenced by changes in the position and intensity of the absorption bands of amide, hydroxyl and silanol groups after gelatin adsorption. The results of thermogravimetric analysis confirm changes in the state of bound water and increased structural complexity of the gels, as evidenced by greater mass losses in the dehydration region and the appearance of additional thermal effects. The combined results indicate that the “superactivity” effect of silica-containing gels is caused by the synergistic action of silicon dioxide and polysaccharide components, which ensures the formation of a structured silica-polysaccharide matrix with an enhanced capacity for protein adsorption. The obtained data expand the current understanding of the mechanisms of action of modern silicacontaining enterosorbents and may be used in the development of effective sorption systems for medical applications.
Instructions for medical use (IMU) serve as the main source of information for safe use by healthcare professionals and patients and accompany each registered drug. IMU combines the functions of documents for both the doctor and the patient, which necessitates the need to balance the scientific completeness of information and its accessibility for non-specialists. In European practice, information about a medicinal product is structured in the form of separate documents: a summary of product characteristics (Summary of Product Characteristics, SmPC), aimed at healthcare professionals, and a package leaflet (Package Leaflet, PL), intended for patients. The aim of the work was to analyze the current state of IMU of medicinal products as an integrated source of information in making informed clinical and pharmaceutical decisions and the transformation of the document in the context of integration into EU legislation. It was found that the IMU, SmPC and PL have a common information basis, but differ in structure, volume and target orientation, where the SmPC is the most complete source of information about the medicinal product for making clinical decisions by healthcare professionals. It was shown that pharmacovigilance plays a key role in the formation and u pdating of information in theSmPC, IMU and PL, but the key difference lies in the methods of reporting adverse reactions and the levels of detail of risks. It was proven that the IMU is a compromise tool that provides access to key information for different categories of users. At the same time, limitations in volume and the need to adapt information may lead to the loss of some of the detailed scientific data fully provided in the SmPC. Certain clinical decisions (availability of clinical data, pharmacokinetics/pharmacodynamics, adverse reactions, drug interactions) involve the analysis of the SmPC by the physician to choose the optimal drug. Pharmaceutical solutions (dosage form, storage conditions, packaging, administration devices, etc.) are strategic approaches of the manufacturer at the stages of development and registration of a medicinal product, which directly affect the content and structure of the IMU, SmPC, PL. The transformation of the IMU in the context of harmonization of Ukrainian l egislation with EUrequirements involves the replacement of the IMU with the SmPC and PL, the use of QRD templates, and the digitalization of information about medicinal products. Standardization of the PL structure, improved readability, and the introduction of modern text-processing technologies ensure the accessibility and comprehensibility of information and support the safe use of medicinal products by patients. The transformation of the IMU into the SmPC and PL contributes to improving the quality of information, the safety of pharmacotherapy, and the efficiency of clinical and pharmaceutical decision-making.
This editorial examines the transformation of the Pharmaceutical Journal and the evolving requirements for modern scientific publications. It focuses on updates to the journal’s editorial policy, improvements in peer review, the development of digital infrastructure, and the principles of academic integrity and open access. Particular attention is paid to the journal’s confirmation as a Category B scientific professional publication and the new opportunities this creates for authors. The author outlines the journal’s strategic priorities, including strengthening its international presence, expanding collaboration with Ukrainian and international researchers, integration into leading international scientometric databases, and further development of digital services. The editorial also addresses the use of artificial intelligence in scholarly publishing and presents a vision of the journal’s future as a modern European scientific publication that combines nearly a century of tradition with international standards.
The modern concept of treatment of infectious urogenital lesions is based on purposeful etiotropic and pathogenetically justified prescription of effective drugs. Bifonazole is an imidazole compound that has long been effectively used in dermatological practice for topical therapy of skin and nails, has high antimycotic activity of a wide spectrum and, at the same time, vaginal forms of it are absent. On the basis of complex studies, the rational composition of vaginal suppositories of biphonazole 0.3 g was proposed, which will expand the range of antimycotic pharmacotherapeutic agents for gynecological practice and will increase the effectiveness of treatment of mycotic lesions of the genitourinary organs. The purpose of this work is to substantiate the optimal temperature regime for the manufacture of vaginal suppositories with biphonazole, which eliminates the negative change in the pharmacotechnological parameters of the dosage form. The objects of thermogravimetric studies were vaginal suppositories with bisphonazole 0.3 g, as well as active and auxiliary substances of this dosage form. Thermogravimetric studies were carried out using a derivatograph Shimadzu DTG-60 (Japan). The test samples were heated in aluminum crucibles in the temperature range of 29 to 300 °C using α-Al2O3 as a reference substance. According to thermogravimetry, biphonazole is a thermally stable compound up to 253 °C with a mass loss of only 1.1 %. The components of the suppository carrier are also quite stable at temperatures up to 100 °C. The nature of the thermal effects on the derivatogram of vaginal suppositories with bifonazole is completely correlated with the thermal effects of the carrier base of the dosage form. Thermogravimetric studies of vaginal suppositories with bisphonazole 0.3 g and their components prove that the components of the composition on a lipophilic carrier (cocoa butter plus 5 % emulsifier No. 1) do not interact with each other and it is practically a mechanical mixture of the constituent ingredients. Carrying out the process of making vaginal suppositories with biphonazole in the temperature range inherent in the production of these dosage forms (70-80 ºC) does not lead to destructive effects on its components and the finished product.
